Robert K. Oldham, MD

About Robert

Dr. Oldham is an internationally recognized oncology/hematology specialist and is regarded as a leading pioneer in the development and use of immunotherapy - the fourth modality in cancer treatment. His primary mission has been to improve the outcomes for his patients with cancer and blood disorders.

Dr. Oldham attended the University of Missouri where his undergraduate studies were in chemical engineering and pre-medical sciences. He completed his internship and residency in Internal Medicine at Vanderbilt in Nashville. He continued his education with a Medical Oncology Fellowship and graduate studies in immunology at the National Cancer Institute (NCI) in Bethesda, Maryland where he served as Clinical Associate in the Radiation Branch and in the Cellular and Tumor Immunology Section of the Laboratory of Cell Biology. Dr. Oldham also completed a fellowship in Paris, France with Professor Georges Mathé, a distinguished bone marrow transplant hematologist.

Extremely active in both research and leadership in cancer treatment, Dr. Oldham has served in multiple roles as a professor and research associate all around the globe. As a founder of multiple oncology divisions and organizations including the Biological Therapy Institute and Bio-therapeutics Incorporated, the Division of Oncology at Vanderbilt University and the Biologic Response Modifiers Program (BRMP) at the National Cancer Institute, Dr. Oldham is a pioneer in the field of oncology.

He holds a Clinical Professorship of Medicine in Hematology/Oncology at the University of Missouri-Columbia and has been a Clinical Professor in the Department of Biomedical Sciences at Florida State University College of Medicine. Additionally, he has served as a consultant in the US and overseas including Gen-Cell (Rhône-Poulenc), Jenner Technologies, Welcome Biotechnology Ltd. and Amersham Corporation in England. He also served as a senior consultant with the American Red Cross, Cell Genesys Inc., Xcyte Therapies and Maxim Pharmaceuticals.

Oldham has founded and served as editor-in-chief of three medical journals: Cancer Biotherapy (now Cancer Biotherapy & Radio­­­­­­­­­­pharmaceuticals), Molecular Biotherapy, and Journal of Biological Response Modifiers (now Journal of Immunotherapy). He is the co-editor of Principles of Cancer Biotherapy’ the first comprehensive textbook on the fourth modality of cancer treatment. He has authored or edited fifteen books on cancer treatment and research.

Additionally, he has contributed nearly 500 papers to the medical/scientific literature and has presented thousands of abstracts, posters, and lectures at various meetings on cancer research and treatment. Dr. Oldham has received many awards and honors. He holds, or has held, membership in 19 professional societies.

Medical Interests Areas of Interest: Editorial Boards:
1992 - 2018 Cancer Biotherapy, Founder, (now Cancer Biotherapy & Radio- pharmaceuticals- Co-Editor-in-Chief)
1990 - 1999 In Vivo, Editorial Board
Natural Immunity and Cell Growth Regulation, Editorial Board
1988 - 1992 Molecular Biotherapy, Founder and Editor-in-Chief
1982 - 1989 Journal of Biological Response Modifiers (now Journal of Immunotherapy) Founder and Editor-in-Chief
1982 - 1985 Cancer Immunology and Immunotherapy, Editorial Board Special Clinical Interests: Publications
Over 440 papers published in the medical/scientific literature-Full bibliography available on request.
Thousands of abstracts, posters and presentations at various meetings on cancer research and treatment
Editor of Principles of Cancer Biotherapy, the first comprehensive textbook on the fourth modality of cancer treatment (Now in Fifth Edition, 2009 - Springer Publishers).
Editor of Principles of Cancer Biotherapy: First Edition, 1987, Raven Press
Second Edition, 1991, Marcel Dekker
Third Edition, 1998, Kluwer Academic Publishers
Fourth Edition, 2004, Kluwer Academic Publishers
Fifth Edition, 2009,Springer-Verlag Publishers
Founding Editor of Cancer Biotherapy, (now Cancer Biotherapy & Radiopharmaceuticals), Molecular Biotherapy and the Journal of Biological Response Modifiers (now Journal of Immunotherapy).
Author or editor of fourteen books on cancer research and treatment
Author of two published novels